Business Wire

NILIT

26.8.2024 21:03:49 CEST | Business Wire | Press release

Share
Samsara Eco and NILIT Team up to Build World-First Nylon 6,6 Recycling Facility

Samsara Eco, the enviro-tech innovator and NILIT, the world’s leader in the production of nylon 6,6 for apparel, have announced plans to explore investment and construction of a nylon 6,6 textile-to-textile recycled polymer production site in South East Asia to help close the loop on nylon 6,6.

Roughly 4 million tonnes of nylon 6,6 is created every year, it is one of the most widely used fibers in the performance apparel and fashion industries. However, it is notoriously difficult to recycle and when blended with other fibres like spandex, it increases the challenge. Together, Samsara Eco and NILIT are seeking to address this issue head-on.

Aiming to be operational by late 2026, the anticipated facility will be uniquely capable of recycling textile waste, producing high-quality recycled nylon 6,6 polymers, for textile brands and manufacturers to seamlessly use in their existing supply chains to create new textile fabrics, infinitely.

“Our vision is to deliver climate repair through infinite recycling. One of the ways we’re achieving this is by creating the first circular pathway for nylon 6,6. Discarded clothing made from nylon 6,6 such as activewear, and even products like car interiors, typically end up in landfill or are incinerated at the end of life, which has dire consequences for our planet,” said Paul Riley, CEO and Founder of Samsara Eco.

Sarah Cook, Chief Commercial and Operations Officer of Samsara Eco also commented on the agreement: “By working with NILIT, we can reverse this trend and give apparel a new life. The MoU agreement is an important step to help brands and the world advance nylon 6,6 circularity and reduce plastic waste. We’re proud to be exploring a pilot recycling facility with NILIT, setting a precedent of what’s possible for future partners globally.”

“NILIT’s partnership with Samsara Eco is a critical step in our multi-pronged strategy to provide the apparel market with premium nylon 6,6 products that have lower environmental impact,” explained Ilan Melamed, NILIT General Manager. “Implementing textile-to-textile recycling solutions will substantially decrease global carbon emissions and reduce the 92 million tonnes of textile waste added to landfills annually. Together, NILIT and Samsara Eco have the potential to produce infinitely recycled nylon 6,6 that delivers outstanding fabric quality and performance while benefitting the planet.”

EosEco™ is the world's first technology to infinitely recycle nylon 6,6 by combining biophysics, chemistry, biology and computer science (such as AI) to create a family of plastic-eating enzymes. The enzymes break down plastic waste, including textiles made from nylon 6,6 into raw materials, which are then seamlessly integrated into existing manufacturing processes to create a truly closed loop. EosEco™ can recycle a breadth of feedstock inputs, including coloured and blended textiles like nylon 6,6 with spandex. EosEco™, together with NILIT’s unique polymerization, spinning and technology will be able to create premium recycled Nylon 6, 6 yarn for global consumption.

About NILIT

Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6,6 yarns designed to empower the apparel industry’s shift to a more sustainable position. Operating internationally, NILIT is the global leader in Nylon 6,6 yarns for apparel, dedicated to creating innovative and sustainable solutions that advance the textile industry.

NILIT will add Samsara Eco’s EosEco™ produced yarn to its innovative SENSIL® preferred portfolio of products which is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.

About Samsara Eco

Samsara Eco is using advanced, enzymatic recycling to end plastic pollution. With breakthrough science, Samsara Eco has developed a new way to break plastic down to its core molecules, which can then be used to recreate brand-new plastic, again and again. Its patented technology, EosEco™ is a first-of-its-kind process that is genuinely better for the planet.

Samsara Eco’s community is united by the shared mission to divert plastic from our landfills and oceans, and eliminate the need to create plastic from fossil fuels, (whether it’s for the bottles we drink from or the clothes we wear) for a cleaner and more sustainable future.

In partnership with the Australian National University (ANU), Samsara Eco launched in 2020 with the backing of Main Sequence and Woolworths Group’s W23. It has raised more than AUD $160M in funding from local and global investors including Breakthrough Victoria, DCVC, Hitachi, lululemon, Temasek, Wildcard Ventures, Wollemi Capital and more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820332060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye